CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 114 enrolled
Drug / intervention
Aspirin 81Mg Ec Tab +1 moredrug
Likely dose
Aspirin 81Mg Ec Tabfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05889468
NCT05889468Phase 4Completed
CompareCT.gov

The Association Between Postpartum Aspirin Use and NT-proBNP Levels as a Marker for Maternal Health Outcomes.

Duke University·interventional·Posted Jun 5, 2023·Updated Jun 4, 2025

In Brief

A Phase 4 clinical trial evaluating Aspirin 81Mg Ec Tab and Placebo for Blood Pressure. Completed, enrolled 114 participants across 1 site.

Detailed Summary

This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between groups. There is currently no data on the maternal health effects associated with continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in the knowledge regarding the utility of low-dose aspirin following delivery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Pressure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedJun 5, 2023
Enrollment StartJul 1, 2023
Primary CompletionMay 21, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.1 years ago

Interventions

Aspirin 81Mg Ec Tabdrug

Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.

Placebodrug

Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.